Fruitflow, a tomato-extract product developed by Provexis, has been found effective to prevent blood clots that risk heart attacka nd strokes without the side-effects of the widely used blood thinner Aspirin.
Fruitflow is a water-soluble tomato concentrate.
Clinical studies using Fruitflow that compared the effects on platelet aggregation of the tomato-extract product and aspirin showed that up to 30 percent reduction from baseline platelet aggregation.
Platelet aggregation can contribute to unwanted clot formation in the bloodstream.
The seven-months long human studies also examined the interactions between Fruitflow and aspirin consumed together.
Aspirin could lead to gastric ulceration and bleeding.
The effect takes place within three hours of consumption and lasts for up to eighteen hours, making it ideal for daily dosage in functional foods or dietary supplements.
Provexis has developed a syrup format for use in food & beverages and a concentrated powder format for tablets and capsules.
Fruitflow syrup is GRAS (Generally Regarded as Safe) by the US FDA and is not regarded as a Novel Food in the EU, clearing it for wide use in foods, beverages and supplements.
In May 2009, the Fruitflow technology was the first to be substantiated by the European Food Safety Authority (EFSA) under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health claim “Helps maintain normal platelet aggregation, which contributes to healthy blood flow”, which was the first wording to be authorised under Article 13(5).
The technology has been granted patents in the EU, US, Australia, Canada and Mexico, with Japan pending. Further patents have been filed for the bioactive components of Fruitflow and for other developmental areas such as deep vein thrombosis and triglyceride lowering.
Discovered by Professor Asim Dutta Roy at the Rowett Institute in 1999, the technology has been developed by the Provexis team in recent years. This development programme includes eight clinical trials.
The product is commercially-ready for delivery in a wide range of food, beverage and dietary supplement formats.
In February, Provexis entered into a long-term alliance agreement with DSM Nutritional Products for exclusive global rights to Fruitflow.DSM Nutritional is a leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries.
This Agreement will provide for a partnership and structure in which DSM and Provexis will develop, market and sell Fruitflow as an ingredient in all formats and territories.
Profits from the Agreement will be shared by the parties on an agreed basis, linked to various performance milestones.
Provexis will continue to support the development of current and future formats of Fruitflow and DSM will contribute with its manufacturing and selling experience and excellence to a successful commercialisation of Fruitflow.
Future claim areas under development include deep vein thrombosis, metabolic syndrome and type-II diabetes.
Provexis is focused on the discovery, development and licensing of technologies for the functional food, dietary supplement and medical food sectors.
The company was originally spun out of the Rowett Institute (now part of the University of Aberdeen) in 1999 to commercialise their tomato extract discovery using venture capital funding. Provexis Limited was reversed into Nutrinnovator in 2005 and its major investors are DSM Venturing and Rising Stars Growth Fund (part of Enterprise Ventures).
The company has additional biotechnology developments, including a joint venture with the University of Liverpool to develop an extract of plantain which aids the treatment of inflammatory bowel disease, and an early stage technology under option from University of Manchester for the prevention and treatment of peptic ulcers.
DSM Nutritional Products is the world’s leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of about EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments